Literature DB >> 31392154

Editorial: early PSA-testing after radical prostatectomy-the truth behind the scenes.

Julian Hanske1, Florian Roghmann1, Joachim Noldus1, Marko Brock1.   

Abstract

Year:  2019        PMID： 31392154      PMCID： PMC6642953          DOI： 10.21037/tau.2019.06.08

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  10 in total

1.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-10-06       Impact factor: 20.096

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.

Authors:  Roderick van den Bergh; Giorgio Gandaglia; Derya Tilki; Hendrik Borgmann; Piet Ost; Christian Surcel; Massimo Valerio; Prasanna Sooriakumaran; Laurent Salomon; Alberto Briganti; Markus Graefen; Henk van der Poel; Alexandre de la Taille; Francesco Montorsi; Guillaume Ploussard
Journal:  Eur Urol Focus       Date:  2017-08-08

Review 4.  Diagnostic associations of gene expression signatures in prostate cancer tissue.

Authors:  Hao G Nguyen; Christopher J Welty; Matthew R Cooperberg
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

5.  Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.

Authors:  Felix Preisser; Felix K H Chun; Raisa S Pompe; Alexander Heinze; Georg Salomon; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  Eur Urol       Date:  2019-02-14       Impact factor: 20.096

6.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.

Authors:  Stephen A Boorjian; R Houston Thompson; Matthew K Tollefson; Laureano J Rangel; Eric J Bergstralh; Michael L Blute; R Jeffrey Karnes
Journal:  Eur Urol       Date:  2011-02-22       Impact factor: 20.096

7.  The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Authors:  Lorenzo Bianchi; Alessandro Nini; Marco Bianchi; Giorgio Gandaglia; Nicola Fossati; Nazareno Suardi; Marco Moschini; Paolo Dell'Oglio; Riccardo Schiavina; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2015-12-31       Impact factor: 20.096

Review 8.  Rising prostate-specific antigen after primary prostate cancer therapy.

Authors:  John F Ward; Judd W Moul
Journal:  Nat Clin Pract Urol       Date:  2005-04

Review 9.  Biomarkers in prostate cancer: what's new?

Authors:  David A Sartori; Daniel W Chan
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

10.  Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Authors:  Nicola Fossati; R Jeffrey Karnes; Michele Colicchia; Stephen A Boorjian; Alberto Bossi; Thomas Seisen; Nadia Di Muzio; Cesare Cozzarini; Barbara Noris Chiorda; Claudio Fiorino; Giorgio Gandaglia; Paolo Dell'Oglio; Shahrokh F Shariat; Gregor Goldner; Steven Joniau; Antonino Battaglia; Karin Haustermans; Gert De Meerleer; Valérie Fonteyne; Piet Ost; Hendrik Van Poppel; Thomas Wiegel; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2017-08-02       Impact factor: 20.096
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.